Amarin Corp Plc (AMRN)

[ralphey]

When I read this I get the sense that AMRN has no clear strategy or plan to combat the generics - 'its out of their control' They seem clueless as to how to combat the generics - he doesn't seem to understand the process of an MD writing the RX and the pharmacist who fills it being clueless as to the indication its written for

The second one has to do obviously with the situation with the generics because today what we are seeing is that a significant number of patients who are indicated for cardiovascular risk indication, which is an indication not approved for the generic, are still getting the generic. And there are things that we can do as Amarin about this and there are things that are out of our control, let's face it. If the generics continue to supply the market beyond what is needed -- I'm being very clear. Beyond what is needed because the indication size that they have is literally 7% to 8% of the market, but if they continue to push more supply, the payers will use it and we have challenges. That's not in our control. There is a legal sort of path to deal with this. What is in our control is what are we doing to secure the fulfillment of our own prescription.

So what we're really focusing on as a metric is what is the fulfillment rate. How many rejections are we getting? Are we truly getting, at the end of the day, every prescription that is written by a physician, fulfilled at the pharmacist at the end of the day? And that's why we have a number of initiatives to drive this level of fulfillment to be much higher.

So these are really the metrics we're focusing on. I -- it's a difficult question, Roanna, but I hope I clarify.